Expert Interview
Discussing the Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
Ticker(s): VRDNInstitution: ASCENTION
- Oculoplastic Surgeon at Ascention in Austin, TX; previously Professor of Ophthalmology at Baylor College of Medicine
- Manages ~120 chronic TED patients
- Clinical and research interests in ophthalmology and oculoplastic surgery, having 20 years of experience and over 120 peer-reviewed publications.
Overall, when this drug is approved, how do you think you will use this agent vs Tepezza?
Regarding hearing impairment, for the Tepezza trials 0% of placebo patients reported it, where as on here, you have 11% of placebo patients reporting it. So even though on a placebo adjusted basis its better than Tepezza, do you think that in the 'real world', hearing impairment might actually be worse than Tepezza?
Can you discuss your clinical practice and research interests, particularly your experience with treating thyroid eye disease (TED) patients?
What are your thoughts on the efficacy and adverse events of Tepezza, especially regarding real-world patient outcomes and safety concerns like hearing loss?
How do you view the expanding use of Tepezza for chronic TED, and what factors influence your decision to recommend surgery over medication in such cases?
Given the recent results of the VRDN-001 trial, how do you compare its efficacy, safety profile, and infusion regimen with Tepezza for treating active TED?
Added By: slingshot_insightsHow do reimbursement practices and insurance approval impact your decision-making when prescribing treatments like Tepezza or newer options like Viridian?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
